JAK2 and myeloproliferative disorder: Ropeginterferon has been shown to be effective in inducing hematologic remissions, lowering JAK2-V617F allelic burden, and reducing rates of thrombosis, while discontinuation occurs in a relatively low number of patients (approx. 25%) when compared to early interferon trials (Kiladjian et al. 2006, 2008), HU treatment (Griesshammer et al. 2019) or even ruxolitinib therapy in other subtypes of MPN (Palandri et al. 2020).